BMO Capital raised the firm’s price target on Regeneron (REGN) to $640 from $600 and keeps an Outperform rating on the shares. The company’s strong Q2 print marks a step of progress in the longer journey of regaining the competitive positioning of the company’s Eylea franchise, though clinical and regulatory missteps continue to weigh on the shares, the analyst tells investors in a research note. Regeneron’s core focus into the second half remains commercial execution and clearance of regulatory hurdles with approval of key Eylea HD label expansions, BMO added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $815 from $810 at Guggenheim
- Regeneron price target raised to $543 from $504 at BofA
- Positive Indicators and Strategic Investments Support Buy Rating for Regeneron
- Regeneron price target raised to $761 from $754 at Morgan Stanley
- Regeneron price target raised to $753 from $750 at Bernstein